MK-677

Description

MK-677 is an orally active, non-peptide compound that functions as a ghrelin receptor agonist and growth hormone secretagogue, leading to increased secretion of growth hormone and insulin-like growth factor 1, potentially enhancing body composition, sleep quality, and bone density.

Overview

MK-677, also known as ibutamoren or L-163,191, is a synthetic, non-peptidic molecule explored for its ability to promote the secretion of growth hormone (GH) and insulin-like growth factor 1 (IGF-1) from the pituitary gland. It operates by acting as an agonist at the ghrelin receptor. Research indicates its potential in various applications, such as addressing growth hormone deficiency, improving body composition, optimizing sleep patterns, and supporting bone health. It has been investigated in multiple clinical settings, with studies ranging from short-term assessments on body composition and sleep to longer-term observations on bone turnover in elderly populations. Clinical investigations into MK-677 have shown promising results in several areas. For body composition, studies have demonstrated its capacity to increase lean muscle mass and enhance IGF-1 levels in diverse populations, including obese individuals on a caloric deficit. Regarding sleep, research suggests that MK-677 can positively influence sleep architecture, particularly increasing the duration of both deep sleep (Stage IV) and REM sleep. Its impact on bone health has also been explored, with evidence pointing to its ability to stimulate bone remodeling markers, suggesting a role in both bone formation and resorption. While possessing an elimination half-life of 4 to 6 hours and being orally active, making it a convenient once-daily agent, MK-677 is categorized as an Investigational New Drug and is not currently FDA-approved for any medical use. Research continues to evaluate its long-term safety and efficacy across different populations. For instance, a study on Alzheimer's disease patients showed increases in IGF-1 but no alteration in disease progression, highlighting the nuanced outcomes often seen in clinical research.

Mechanism of Action

This compound mimics the action of ghrelin, binding to growth hormone secretagogue receptors (GHS-R) and thereby stimulating the pituitary gland to release growth hormone (GH) and insulin-like growth factor 1 (IGF-1). Unlike many other compounds, it achieves this without significantly elevating cortisol levels. Its mechanism specifically avoids interfering with the body's natural negative feedback loops for GH regulation. Importantly, this secretagogue is not a somatostatin analog.

Benefits

• •Improved body composition
• •Enhanced sleep quality and duration
• •Aids in bone formation and resorption
• •Potential treatment for growth hormone deficiency

Dosing Notes

Typical research protocols involve administering MK-677 once daily, often in the range of 12.5 to 25 mg. Due to the time required for notable increases in growth hormone levels, administration for cycles of 16 to 20 weeks, followed by a break, is common in research settings.

Reported Side Effects

• •Increased fasting blood glucose levels
• •Decreased insulin sensitivity
• •Increased appetite
• •Mild lower extremity edema
• •Mild muscle pain
• •Decreased LDL cholesterol
• •Increased cortisol levels (modest)

Safety Notes

Reported side effects include transient increases in fasting blood glucose and appetite, and mild peripheral edema or muscle pain. A notable caution arose from a study involving elderly hip fracture patients, which was halted due to a potential increase in congestive heart failure incidence, suggesting it may not be suitable for all populations. Long-term safety data is still being gathered, and the compound does not have FDA approval.

Scientific References